Nearly 60 global healthcare companies have been impacted in some way by the efforts of state officials to obtain execution drug supplies, and where necessary have taken action to mitigate the risks associated with the diversion and misuse of their products in lethal injection executions:
- Abbott
- AbbVie
- Accord
- Actavis
- Akorn
- Alvogen
- Amgen
- Amerisource
- APP
- AstraZeneca
- Athenex
- AuroMedics
- Baxter
- B Braun
- BD Rx
- Cadila Healthcare
- Cardinal Health
- Celgene
- Centene
- Custopharm
- Daiichi Sankyo
- Eli Lilly
- Endo
- Emcure
- Fresenius Kabi
- Ganpati Exim
- Gland Pharma
- GlaxoSmithKline
- Henry Schein
- Hikma
- Heritage
- Hospira
- Intas
- Janssen
- Jiangsu Hengrui
- Johnson & Johnson
- Kayem
- Luitpold
- Lundbeck
- McKesson
- MedPharmex
- Mylan
- Naari
- Novartis
- Par
- Pfizer
- Purdue
- Renaissance
- Roche
- Sagent
- Sandoz
- Shrenik Pharma
- Sun Pharma
- Tamarang
- Teva
- Valeant
- X‐Gen
- Zydus